Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Provectus Pharmaceuticals has received allowance for its US patent application protecting therapeutic agents based on a novel photoactive analog of its lead photodynamic product PH-10 from the US Patent and Trademark Office.
Subscribe to our email newsletter
The pending patent covers systemic therapeutic agents that are used in conjunction with visible light for photodynamic treatment of cancer, skin diseases, and other tissue disorders. The active compound was developed to improve the efficiency and specificity of the photodynamic process, potentially allowing treatment to be achieved quickly using minimal amounts of light.
Craig Dees, CEO of Provectus, said: “While we remain focused on clinical development of our lead therapeutic products, PV-10 for cancer and PH-10 for dermatology, this new patent solidifies an important longer-term opportunity in our development pipeline.”